Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Breast cancer, female
Trial Type:  Prevention
Trial Status:  Closed
Sponsor of Trial:  NCI
Results 1-25 of 61 for your search:
Start Over
Women in Steady Exercise Research [Formerly Women, Oxidative Stress, Exercise and Estrogens (WOSEE)]
Phase: Phase III, Phase II
Type: Diagnostic, Prevention
Status: Completed
Age: 18 to 30
Sponsor: NCI, Other
Protocol IDs: CDR0000511819, U54CA116849, UMN-0505M69867, NCT00393172
Women's Healthy Eating and Living Study
Phase: Phase III
Type: Prevention, Treatment
Status: Closed
Age: 18 to 70 at time of diagnosis
Sponsor: NCI, Other
Protocol IDs: UCSD-980919, CDR0000066920, UCSD-WHEL, NCI-G99-1508, NCT00003787
Women's Health Initiative (WHI)
Phase: Phase III
Type: Health services research, Natural history/Epidemiology, Prevention
Status: Completed
Age: 50 to 79
Sponsor: NCI, NHLBI
Protocol IDs: 114, NCT00000611
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
Phase: Phase III
Type: Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065314, CALGB-49901, S9630, U10CA037429, U10CA032102, SWOG-S9630, SWOG-9630, NCT00002920
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Phase: Phase III
Type: Prevention
Status: Completed
Age: 35 and over
Sponsor: NCI, Other
Protocol IDs: NSABP P-2, CDR0000067081, NCT00003906
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
Phase: Phase III
Type: Prevention
Status: Closed
Age: 55 and over
Sponsor: NCI, Other
Protocol IDs: CAPS08-15024, R01CA129488-01A2, NCT01052051
Phase II Study of DiFluoroMethylOrnithine (DFMO) in Breast Dysplasia with Biomarker Abnormalities (Summary Last Modified 05/1999)
Phase: Phase II
Type: Prevention
Status: Closed
Age: 30-55 with exceptions
Sponsor: NCI
Protocol IDs: KUMC-HSC-6916-96, NCI-P97-0080
Phase II Randomized, Double Blind, Placebo-Controlled Study of Eflornithine (DFMO) in Women with Breast Neoplasia (Summary Last Modified 03/98)
Phase: Phase II
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UAB-9509, NCI-P97-0082
Phase II Trial of Dietary Fatty Acids: Roles in Hormonally Mediated Cancers in Normal Premenopausal Women (Summary Last Modified 06/98)
Phase: Phase II
Type: Prevention
Status: Closed
Age: 18-35
Sponsor: NCI
Protocol IDs: UMN-9509M10234, NCI-P97-0108
Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer
Phase: Phase II
Type: Prevention
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: ID94-029, P30CA016672, MDA-ID-94029, NCI-P97-0113, CDR0000065829, NCT00003099
Raloxifene in Preventing Breast Cancer in Premenopausal Women
Phase: Phase II
Type: Prevention
Status: Completed
Age: 23 to 47
Sponsor: NCI
Protocol IDs: CDR0000066428, NCI-98-C-0123, MB-402, NCT00019500
Phase II Randomized Study of Exemestane and Raloxifene in Postmenopausal Women With a History of Stage 0 (Ductal Carcinoma in Situ), I, II, or III Breast Cancer Who Have No Clinical Evidence of Disease
Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-99017, NCI-G99-1662, NCT00004247
Phase II Randomized Study of Tamoxifen and Fenretinide for the Prevention of Breast Cancer
Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: CNR-IEO-007, U01-CA77188-01
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: 040044, 04-C-0044, NCT00073073
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
Phase: Phase II
Type: Prevention
Status: Completed
Age: 21 to 48
Sponsor: NCI, Other
Protocol IDs: 02164, P30CA033572, CHNMC-IRB-02164, CDR0000355156, NCI-2011-00975, NCT00080756
Letrozole in Preventing Breast Cancer in Postmenopausal Women
Phase: Phase II
Type: Prevention
Status: Completed
Age: 35 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000375585, DFCI-00024, UCLA-0210012-02, NCT00090857
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE-CCF-4713, P30CA043703, NCT00253539
Soy Isoflavones and Breast Cancer Risk Reduction
Phase: Phase II
Type: Prevention
Status: Closed
Age: 30 to 42
Sponsor: NCI
Protocol IDs: 03-260, UTMB GCRC #635, R01CA095545, M01RR000073, 1UL1RR029876-01, NCT00204490
Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: JHOC-J0485, CDR0000477214, P50CA088843, P30CA006973, JHOC-J0485, SKCCC-J0485, J0485, JHOC-SKCCC-J0485, JHOC-04100404, NCT00334542
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: J05100, CDR0000485361, P30CA006973, JHOC-J05100, JHOC-SKCCC-J05100, J05100, NCT00354640
Study of Breast Cancer Prevention by Letrozole in High Risk Women
Phase: Phase II
Type: Prevention
Status: Closed
Age: 30 to 69
Sponsor: NCI, Other
Protocol IDs: 10587, CFEM345AUS45, 5R01CA122577-03, NCT00579826
Green Tea and Reduction of Breast Cancer Risk
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 50 to 64
Sponsor: NCI, Other
Protocol IDs: 0806M36121, NCT00917735
Phase IIb Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer
Phase: Phase II
Type: Prevention
Status: Closed
Age: 25 and older
Sponsor: NCI, Other
Protocol IDs: NCI 04B3, NWU03-1-04, NU-NWU03-1-04, NU-NCI-04B3, NU-0835-030, NCT00290758
Start Over